Population enrichment designs: Case study of a large multinational trial

Journal of Biopharmaceutical Statistics

Volumn 21, Issue 4, 2011, Pages 831-845

  Mehta, Cyrus R ^a   Gao, Ping ^b  

^a Cytel Incorporated   (United States)

^b MEDICINES COMPANY   (United States)

Author keywords

Adaptive; Adaptive cardiovascular design; Group sequential; Sample size re estimation; Subgroup analysis; Subset selection

Indexed keywords

ARTICLE; HUMAN; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZATION; SAMPLE SIZE; SIMULATION; STUDY DESIGN; SYSTEMATIC ERROR; TREATMENT PLANNING;

CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; MODELS, STATISTICAL; MULTICENTER STUDIES AS TOPIC; OUTCOME ASSESSMENT (HEALTH CARE); SAMPLE SIZE;

EID: 79957509147     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543406.2011.554129     Document Type: Article

References (15)

1. Bauer, P., Keiser, M. (1999). Combining different phases in the development of medical treatments within a single trial. Statistics in Medicine 18:1833-1848. (Pubitemid 29364054)
2. Brannath, W., Zuber, E., Branson, M., Bretz, F., Gallo, P., Posch, M., Racine-Poon, A. (2009). Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology. Statistics in Medicine 28:1445-1463.
3. East: Advanced Clinical Trial Design, Simulation and Monitoring System. (2010). Version 5.4. Cambridge, MA: Cytel Corporation.
4. Freidlin, B., Simon, R. (2005). Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clinical Cancer Research 11(21):7872-7878. (Pubitemid 41611633)
5. Freidlin, B., Jiang, W., Simon, R. (2010). The cross-validated adaptive signature design. Clinical Cancer Research 16(2):691-698.
6. Food and Drug Administration. (2010). Guidance for Industry: Adaptive Design for Clinical Trials for Drugs and Biologics. Washington DC: U.S. Food and Drug Administration, Center for Drug Evaluation Research and Center for Biologics Evaluation Research.
7. Hommel, G (2001). Adaptive modifications of hypotheses after an interim analysis. Biometrical Journal 43(5):581-589. (Pubitemid 33588682)
8. Hwang, I. K., Shih, W. J., DeCani, J. S. (1990). Group sequential designs using a family of type 1 error probability spending functions. Statistics in Medicine 9:1439-1445.
9. Jennison, C., Turnbull, B. W. (2000). Group Sequential Methods With Applications to Clinical Trials. London: Chapman and Hall/CRC.
10. Lan, G. K. K., DeMets, D. L. (1983). Discrete sequential boundaries for clinical trials. Biometrika 70:659-663.
11. Marcus, R., Peritz, E., Gabriel, K. R. (1976). On closed testing procedures with special reference to ordered analysis of variance. Biometrika 63:655-660.
12. Mehta, C. R., Gao, P., Bhatt, D. L., Harrington, R. A., Skerjanec, S., Ware, J. H. (2009). Optimizing trial design: sequential, adaptive and enrichment strategies. Circulation 119:597-605.
13. Müller, H-H., Schäfer, H. (2001). Adaptive group sequential designs for clinical trials: Combining the advantages of adaptive and of classical group sequential approaches. Biometrics 57:886-891. (Pubitemid 32801186)
14. Tsiatis, A. A., Rosner, G. L., Mehta, C. R. (1984). Exact confidence intervals following a group sequential test. Biometrics 40:797-803.
15. Wang, S. J., O'Neill, R. T., Hung, H. M. J. (2007). Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharmaceutical Statistics 6:227-244. (Pubitemid 47455262)